Brief report : High MET overexpression does not predict the presence of MET exon 14 splice mutations in NSCLC : results from the IFCT Predict.amm study.

Date publication

octobre 2019

Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BEAU-FALLER Michèle

Tous les auteurs :
Baldacci S, Figeac M, Antoine M, Descarpentries C, Kherrouche Z, Jamme P, Copin MC, Tulasne D, Nanni I, Beau-Faller M, Melaabi S, Levallet G, Quoix E, Moro-Sibilot D, Friard S, Missy P, Barlesi F, Cadranel J, Cortot AB

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31605799

Résumé

MET exon 14 splice site (METex14) mutations were recently described in Non Small Cell Lung Cancer (NSCLC) and reported to correlate with efficacy of MET tyrosine kinase inhibitors. High diversity of these alterations make them hard to detect by DNA sequencing in clinical practice. Because METex14 mutations induce increased stabilization of the MET receptor, it is anticipated that these mutations are associated with MET overexpression. We aim to determine whether NSCLC with high MET overexpression could define a subset of patients with a high rate of METex14 mutations.

Mots clés

MET, immunohistochemistry, next generation sequencing, non small cell lung cancer, receptor tyrosine kinase

Référence

J Thorac Oncol. 2019 Oct 9;: